{
    "clinical_study": {
        "@rank": "144432", 
        "acronym": "PEChina", 
        "brief_summary": {
            "textblock": "The purpose of this study is to compile real-world clinical outcomes data for the PROMUS\n      Element\u2122 Everolimus-Eluting Coronary Stent System (PROMUS Element Stent System)in routine\n      clinical practice in China."
        }, 
        "brief_title": "Post-Approval Study of PROMUS Element\u2122 in China", 
        "completion_date": {
            "#text": "December 2018", 
            "@type": "Anticipated"
        }, 
        "condition": "Coronary Artery Disease", 
        "condition_browse": {
            "mesh_term": [
                "Coronary Artery Disease", 
                "Myocardial Ischemia", 
                "Coronary Disease"
            ]
        }, 
        "detailed_description": {
            "textblock": "Everolimus-eluting stents have been studied extensively in ongoing clinical studies. The\n      safety and effectiveness of the everolimus drug and polymer combination have been studied\n      extensively in the SPIRIT Clinical Trial Program. The PROMUS Element stent is currently\n      being studied in the PLATINUM Clinical Trial Program. The PROMUS Element stent is also being\n      evaluated in PROMUS Element Plus US post-approval studies and the ongoing Platinum China\n      study. This study is designed to provide post-market surveillance information on the PROMUS\n      Element\u2122 Everolimus-Eluting Coronary Stent System (PROMUS ElementStent System) after it has\n      been approved by SFDA (State of Food and Drug Administration) in China. The study will\n      evaluate clinical outcomes for subjects receiving the PROMUS Element stents over 5 years in\n      a real world setting according to post approval requirements from SFDA."
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Subject must be at least 18 years of age\n\n          -  Subject understands and provides written informed consent\n\n          -  Subject who is clinically indicated and will have an attempt of  at least one PROMUS\n             Element stent OR Subject who is clinically indicated and was implanted with at least\n             one PROMUS Element stent\n\n          -  Subject is willing to comply with all protocol-required follow-up evaluation\n\n        Exclusion Criteria:\n\n          -  Exclusion criteria is not required in the PROMUS Element China Post-Approval study\n             which is an \"all comers\" study."
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "N/A", 
            "minimum_age": "18 Years", 
            "sampling_method": "Non-Probability Sample", 
            "study_pop": {
                "textblock": "All subjects who are candidates for coronary artery stenting, signed the informed consent\n        form and eligible to receive a PROMUS Element stent will be evaluated for enrollment in\n        this study."
            }
        }, 
        "enrollment": {
            "#text": "2000", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "August 30, 2012", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01677585", 
            "org_study_id": "S2288"
        }, 
        "is_fda_regulated": "No", 
        "lastchanged_date": "August 30, 2012", 
        "location": {
            "facility": {
                "address": {
                    "city": "Hangzhou", 
                    "country": "China"
                }, 
                "name": "Second Affliated Hosptial Zhejiang University College of Medicine"
            }, 
            "investigator": {
                "last_name": "Mei Xiang Xiang, Professor", 
                "role": "Sub-Investigator"
            }, 
            "status": "Not yet recruiting"
        }, 
        "location_countries": {
            "country": "China"
        }, 
        "number_of_groups": "1", 
        "official_title": "PROMUS Element\u2122 China Post-Approval Study", 
        "overall_contact": {
            "email": "Shujuanlynn.li@bsci.com", 
            "last_name": "Shu Juan Li, MS"
        }, 
        "overall_official": {
            "affiliation": "Second Affliated Hosptial Zhejiang University College of Medicine", 
            "last_name": "Jian'an Wang, Professor", 
            "role": "Principal Investigator"
        }, 
        "overall_status": "Not yet recruiting", 
        "oversight_info": {
            "authority": "China: Food and Drug Administration", 
            "has_dmc": "No"
        }, 
        "phase": "N/A", 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01677585"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "source": "Boston Scientific Corporation", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Boston Scientific Corporation", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "August 2012", 
        "study_design": "Observational Model: Cohort, Time Perspective: Prospective", 
        "study_type": "Observational", 
        "verification_date": "August 2012"
    }
}